In human cellular models, JEL3108 significantly reduced TNF-alpha, IL-1-beta, and IL-6 markers
Learn how GHK-Cu could potentially benefit your patients in our latest blog article.
Women experiencing menstrual changes while taking tirzepatide can implement several strategies to monitor and manage these alterations effectively
The needle is thin and the injection itself takes seconds
In some embodiments is an enhanced viscosity formulation, comprising from about 0.1 mM and about 100 mM of an active agent, a pharmaceutically acceptable viscosity enhancer or viscosity modulating agent, and water for injection, the concentration of the viscosity enhancer or viscosity modulating agent in the water being sufficient to provide an enhanced viscosity formulation with a final viscosity from about 100 to about 100,000 cP
This product bundle is supplied strictly for laboratory and research purposes and is not intended for human or animal consumption